Combination antitumor therapy with lentinan and bacterial lipopolysaccharide against murine tumors.
The antitumor effects of lentinan and bacterial lipopolysaccharide (LPS) were studied. Combined treatment with lentinan and LPS was very effective against Ehrlich carcinoma in ddY mice, and the syngeneic mammary carcinoma MM46 in C3H/He mice. Studies on the effective doses and times of administration showed that a single injection of lentinan plus LPS 12 days after subcutaneous inoculation of these tumors caused complete regression in 60 approximately 90% of the animals; complete regression of MM46 carcinoma was seen in 83% of the animals.
D000818:Animals; D002286:Carcinoma, Ehrlich Tumor / Q000628:therapy*; D004926:Escherichia coli; D007912:Lentinan / Q000627:therapeutic use*; D008070:Lipopolysaccharides / Q000627:therapeutic use*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D011134:Polysaccharides / Q000627:therapeutic use*
D008070:Lipopolysaccharides; D011134:Polysaccharides; D007912:Lentinan